Indevus Pharmaceuticals signs development agreement with Teva Pharmaceutical for Pagoclone - MarketLine Financial Deals

Indevus Pharmaceuticals signs development agreement with Teva Pharmaceutical for Pagoclone

Indevus Pharmaceuticals signs development agreement with Teva Pharmaceutical for Pagoclone - MarketLine Financial Deals
Indevus Pharmaceuticals signs development agreement with Teva Pharmaceutical for Pagoclone
Published Sep 26, 2008
3 pages — Published Sep 26, 2008
Price US$ 45.00  |  Buy this Report Now

About This Report

  
Abstract:

Indevus Pharmaceuticals, Inc., a US-based specialty pharmaceutical company, has signed a development, license, and commercialization agreement with Teva Pharmaceutical Industries, Ltd., an Israel-based pharmaceutical company engaged in the development, production, and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients, for the exclusive worldwide rights to Pagoclone for the treatment of Stuttering.

  
Source:
Document ID
MA00119_080929
Country
Country
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Indevus Pharmaceuticals signs development agreement with Teva Pharmaceutical for Pagoclone" Sep 26, 2008. Alacra Store. Dec 11, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Indevus-Pharmaceuticals-signs-development-agreement-with-Teva-Pharmaceutical-for-Pagoclone-2052-74>
  
APA:
MarketLine Financial Deals. (2008). Indevus Pharmaceuticals signs development agreement with Teva Pharmaceutical for Pagoclone Sep 26, 2008. New York, NY: Alacra Store. Retrieved Dec 11, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Indevus-Pharmaceuticals-signs-development-agreement-with-Teva-Pharmaceutical-for-Pagoclone-2052-74>
  
US$ 45.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.